Barrier Therapeutics, Inc., a pharmaceutical company developing and commercializing products in the field of dermatology, today announced results of a Phase 2a proof-of-concept study of oral Hivenyl? in the treatment of moderate to severe itching related to atopic dermatitis which indicate that Hivenyl significantly reduces itch symptoms without signs of sedation. Hivenyl is an oral formulation ...
From: biz.yahoo.com
TM) in the Treatment of Itch in Atopic Dermatitis
Posted by Ruslan Abuzant at 2:30 PM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment